To assess the therapeutic effects and safety of ultrasound-guided percutaneous lauromacrogol injection therapy for abdominal and pelvic cystic lesions with different sizes.

Twenty-three cases of hepatic cysts, 16 cases of renal cysts, 23 cases of endometrial cysts of the ovary, 8 cases of lymphatic cysts after uterectomy and 6 cases of pelvic fluid collections were included in this study. All the patients were treated at the Shanxi Coal Center Hospital from December 2012 to December 2014 using ultrasound-guided percutaneous sclerosing lauromacrogol injection therapy. The lesions were grouped as a cyst diameter≥8 cm group and a cyst diameter<8 cm group. The side effects and safety were observed. The therapeutic effects was observed and evaluated using conventional ultrasound 3, 6 and 12 months after treatment. The cyst was considered cured if it completely disappeared and effective if it shrank more than 75% in volume but did not completely disappeared.

The therapeutic effects of sclerosing lauromacrogol injection therapy for abdominal and pelvic cystic lesions were significant, with a total effective rate of 96.1% and 100%, respectively, at 3 and 6 months after treatment. The cure rate was 100% at 12 months after treatment. The therapeutic effects at 3 and 6 months for the cyst diameter<8 cm group were significantly higher than those for the cyst diameter≥8 cm group (P<0.01). The rates of adverse effects had no significant difference between the two groups (P<0.01).

Ultrasound-guided percutaneous lauromacrogol injection therapy for abdominal and pelvic cystic lesions is a simple, convenient, feasible, and effective method with little side effects.